- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT07686705
Intravenous Versus Intra-articular Tranexamic Acid for Visual Clarity During Arthroscopic Rotator Cuff Repair
The Effect of Intravenous Versus Intra-articular Tranexamic Acid on Visual Clarity During Arthroscopic Rotator Cuff Repair: A Prospective, Randomized, Double-blind Controlled Trial
This single-center, prospective, randomized, double-blind controlled trial evaluated whether intravenous (IV) or intra-articular (IA) administration of tranexamic acid (TXA) improves intraoperative visual clarity, compared with a no-TXA control, during arthroscopic rotator cuff repair. Patients with rotator cuff tears were randomly allocated to one of three groups: a control group receiving no TXA; an IA group in which 500 mg of TXA was added to each 1 L of normal-saline irrigation fluid; and an IV group receiving 1000 mg of TXA intravenously 10 minutes before surgery. The operating surgeon graded visual clarity on a 0-10 numeric scale at the end of each of six predefined surgical stages. Secondary outcomes included total operative time, estimated blood loss, irrigation-fluid volume, the number of irrigation-pressure increases, postoperative shoulder swelling, and postoperative day 1 pain.
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Studietype
Registrering (Faktiske)
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiesteder
-
-
Seoul
-
Seoul, Seoul, Sør -Korea, 05030
- Konkuk University Medical Center
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Age 18-80 years
- Diagnosed with a rotator cuff tear
- Failure of conservative treatment for more than 3 months
- Rotator cuff deemed repairable on magnetic resonance imaging
Exclusion Criteria:
- Known hypersensitivity to tranexamic acid
- Previous cerebrovascular accident
- Coronary stent or other history of thromboembolic disease
- Anticoagulant therapy
- Uncontrolled hypertension (systolic pressure > 180 mmHg)
- Abnormal prothrombin time or activated partial thromboplastin time
- Acute traumatic rotator cuff tear
- Irreparable rotator cuff tear
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Dobbelt
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Ingen inngripen: Control
No tranexamic acid; arthroscopic rotator cuff repair performed with plain normal-saline irrigation. |
|
|
Eksperimentell: Intra-articular TXA
Tranexamic acid 500 mg added to each 1 L of normal-saline irrigation fluid during arthroscopic rotator cuff repair. |
500 mg of tranexamic acid added per 1 L of normal-saline irrigation fluid. |
|
Eksperimentell: Intravenous TXA
Tranexamic acid 1000 mg administered intravenously 10 minutes before surgery; plain normal-saline irrigation as in the control group. |
1000 mg of tranexamic acid administered intravenously 10 minutes before surgery. |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Intraoperative visual clarity
Tidsramme: Intraoperatively, at the end of each of the six surgical stages
|
Surgeon-rated clarity of the arthroscopic surgical field on a 0-10 numeric scale (0 = poorest visualization, 10 = optimal visualization), scored at the end of each of six surgical stages: glenohumeral procedure, subacromial bursectomy, acromioplasty, rotator cuff inspection, medial-row repair, and lateral-row repair. |
Intraoperatively, at the end of each of the six surgical stages
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Total operative time
Tidsramme: Intraoperative (duration of surgery)
|
Total duration of the surgical procedure. |
Intraoperative (duration of surgery)
|
|
Estimated blood loss
Tidsramme: postoperative day 1
|
Estimated blood loss calculated from serum hemoglobin measured before and after surgery using the formula described by Good et al. |
postoperative day 1
|
|
Irrigation-fluid volume
Tidsramme: Intraoperatively, from skin incision to skin closure (duration of surgery)
|
Total volume of irrigation fluid used during the procedure. |
Intraoperatively, from skin incision to skin closure (duration of surgery)
|
|
Number of irrigation-pressure increases
Tidsramme: Intraoperatively, from skin incision to skin closure (duration of surgery)
|
Number of times the irrigation pump pressure was increased to control bleeding affecting the surgical field |
Intraoperatively, from skin incision to skin closure (duration of surgery)
|
|
Postoperative shoulder swelling
Tidsramme: Baseline (pre-operative) and postoperative day 1
|
Shoulder circumference and diameter measured at the axillary and deltoid sites with the arm abducted ~30 degrees, compared between pre-operative and postoperative day 1 |
Baseline (pre-operative) and postoperative day 1
|
|
Postoperative pain
Tidsramme: Pain assessed using the Visual Analog Scale (VAS) for pain, ranging from 0 (no pain) to 10 (worst imaginable pain); higher scores indicate worse outcome, on postoperative day 1
|
Pain assessed using a visual analog scale (VAS) on postoperative day 1 |
Pain assessed using the Visual Analog Scale (VAS) for pain, ranging from 0 (no pain) to 10 (worst imaginable pain); higher scores indicate worse outcome, on postoperative day 1
|
Samarbeidspartnere og etterforskere
Sponsor
Etterforskere
- Hovedetterforsker: Seok Won Chung, MD, Konkuk University Medical Center
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- 2022-12-017
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
IPD-planbeskrivelse
There is no plan to share individual participant data.
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .